Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASART-2: BCD-055 vs Remicade in Ankylosing Spondylitis
NCT02762812Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Zessly in ankylosing spondylitis (AS), sponsored by BIOCAD. Started Jan 2016; status: completed.
02
Drugs
Zessly
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02762812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762812.